Context

Ureteral stones are a common painful condition often requiring medical care, although treatment is usually symptomatic as most stones pass within 6 weeks.1 ,2 Failed expectant management, obstruction and infection are the most common reasons for intervention. Therapies that facilitate stone passage will thereby reduce the symptom duration, need for intervention and probability of complications. Ureteric smooth muscle relaxants have been studied as potential medical expulsive therapies (MET) and the most recent systematic review advocates their use. However, the high risks of selection, allocation and ascertainment bias in the included trials and the inexplicit and subjective primary outcome resulted in high heterogeneity.3 This …